The world’s best preclinical neuroscience
For more than 30 years, in collaboration with some of the best partners in the world, Atuka’s scientists have continued to advance both knowledge and research techniques in the field of Parkinson’s disease and beyond.
BEHIND THE SCIENCE
-
Parkinson’s disease prevalence is soaring—but is there a good news story hidden in the data?
As Parkinson’s becomes the fastest-growing neurological disorder worldwide, its rising prevalence raises urgent questions about public health and economic impact. Could improved diagnosis, treatment, and life expectancy offer a hidden silver lining within the statistics?
-
Highlights from Neuroscience 2024
At the annual summit of the Society for Neuroscience in Chicago, it was clearer than ever that collaboration and advancing technologies are central to moving the field forward.
-
New frontiers in inflammasome therapeutics
Insights from Atuka’s recent visit to the 6th Annual Inflammasome Summit in Boston.
-
What the market overlooked in Seelos’s recent trehalose study
Atuka’s Jonathan Brotchie and Patrick Howson take a deeper look at the top-line results for IV trehalose, an ALS treatment, and see signs of potential for the compound that the market may have missed.
-
Tavapodon offers great promise as a new therapeutic for Parkinson’s disease
On the encouraging topline results from Cerevel Therapeutics’ Phase III TEMPO-3 trial for tavapadon, a D1/D5 dopamine receptor partial agonist.
WHITE PAPER
Optimizing Preclinical Studies for Parkinson’s Disease Therapeutics
Strategies to optimize preclinical study design for therapeutic development and reduce translational risk.
WHITE PAPER
The future of gene therapy from a pre-clinical perspective
The potential of gene therapies is finally being realized and these therapies can deliver life-changing treatments for a broad range of disorders.
Atuka’s Chief Innovation Officer Dr Patrick A. Howson explores the past, present, and future of gene therapy.
Published papers
Atuka’s scientists have been publishing groundbreaking neuroscience research for many decades, often in collaboration with other renowned leaders in our field. The peer-reviewed papers collected below track the evolution of both our ongoing research and the field more broadly.
-
New insights into the organization of the basal ganglia
/ 10 Citations -
Serotonin and Parkinson’s disease: On movement, mood, and madness
/ 136 Citations -
Mechanisms compensating for dopamine loss in early Parkinson disease
/ 72 Citations -
/ 36 Citations -
/ 36 Citations -
/ 35 Citations -
Non-dopaminergic treatments in development for Parkinson’s disease
/ 93 Citations -
/ 31 Citations -
Dietary resveratrol administration increases MnSOD expression and activity in mouse brain
/ 93 Citations -
Striatal histone modifications in models of levodopa‐induced dyskinesia
/ 82 Citations -
/ 61 Citations -
/ 7 Citations -
/ 79 Citations -
/ 32 Citations -
/ 67 Citations -
/ 360 Citations -
Striatal delta opioid receptor binding in experimental models of Parkinson’s disease and dyskinesia
/ 19 Citations -
/ 12 Citations -
Novel pharmacological targets for the treatment of Parkinson’s disease
/ 230 Citations -
/ 10 Citations
TALK TO OUR EXPERTS
Advance your therapeutic program
Get the latest science from Atuka
Sign up to receive our quarterly newsletter featuring the latest developments in Parkinson’s disease research.